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The first total syntheses of newly isolated polyazole natural products azolemycins A-D, along with the5
synthesis of the tetra-oxazole non-natural analogue, are described.
Introduction
Azolemycins A-D are compounds recently isolated from the soil
bacterium, Streptomyces sp. FXJ1.264.1 A combination of mass
spectrometry and 1D and 2D NMR spectrometry identified the10
structure as a modified heptapeptide, with four linked azoles and
an N-terminal oxime. The major isolated azolemycins are the N-
hydroxy derivative with the greater proportion as the E-oxime
geometric isomer 1a, named azolemycin A and the lesser
proportion as the Z- geometric isomer 1b, named azolemycin B15
(Fig. 1). The minor isolated azolemycins differ only in containing
an N-methoxy group and again were isolated as the E-isomer 2a
and the Z-isomer 2b (azolemycins C and D respectively).
20
Figure 1 Azolemycins A-D.
The biosynthesis of the azolemycins has been described,1 and is
believed to involve the posttranslational modification of a
ribosomally-biosynthesised 7 amino-acid precursor. The oxime
functional group is believed to occur from a previously unknown25
posttranslational modification, apparently utilizing a flavin-
dependent monooxygenase to catalyse the oxidation of an N-
terminal valine residue to the corresponding oxime.1 Oxime-
containing natural products are unusual, and those reported,
including caerulomycin A, althiomycin, collismycin A and30
nocardicins A and B,2 result from nonribosomal peptide
synthesis.
Until the 1980s, very few thiazole and oxazole-containing
natural products were known, but an increasing array have since
been identified, particularly derived from marine sources.3 These35
products range from single oxazoles and thiazoles to more
complicated linked chains or macrocycles of concatenated azoles.
The combination of potent biological activity of many of these
azole products and the exciting synthetic challenges they pose has
made them extremely attractive targets for total syntheses,4 and a40
wide range of reagents have been developed to allow for this.5
Polyazoles, or polyazole-containing, natural products made by
total synthesis range from the relatively simple linked bis- and
triazole motifs, as found in the hennoxazoles,6 muscorides,7
bleomycins,8 and myxothiazols,9 to more complicated45
macrocyclic molecules such as the heptazole telomestatin, the
related YM-216391, IB-01211 and more recently, plantazolicin.10
4b, 11
Synthetic Strategy
Our chosen disconnection of the azolemycins involved a50
convergent synthesis, with late stage formation of the central
thiazole, similar to the strategy used in the synthesis of YM-
216391.11a The disconnection gave four distinct units: the
isopropyl oxime 3, the left-hand mixed bisoxazole fragment 4,
the right-hand methyl oxazole 5 and the isoleucine methyl ester 655
(figure 2).
Figure 2 Preliminary disconnections for the synthesis of
azolemycin A
As we planned to synthesise the thiazole from serine, the60
tetraazole core could be divided into two repeating serine-
threonine dimers, corresponding to a common threonine derived
oxazole 5. We therefore further disconnected the AB unit 4 into
oxazole 8 and Boc-L-valine, 7 (figure 2). The protected oxazole
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building block 5 was synthesised from the diprotected Boc-serine
acetonide 10. An HOBt/EDCI peptide coupling gave the
threonine dipeptide 11 in excellent yields. Oxidation of the
threonine residue using the Parikh-Doering conditions,12 and
cyclodehydration using PPh3/I2/NEt3, as described by Wipf,7c5
gave the oxazole 5 (scheme 1). In some reaction batches some
unreacted alcohol 11 was carried through, with ketone 12, to the
cyclodehydration step. In these cases, the elimination product 13
was obtained and this was extremely difficult to separate from
oxazole 5. We therefore performed a Sharpless dihydroxylation10
on the mixture of alkene 13 and oxazole 5.13 This chemoselective
procedure did not affect the oxazole but, as predicted, a simple
aqueous work-up afforded only the clean oxazole 5. We propose
that the alkene 13 formed an unstable diol that decomposed to
give two non-isolated water soluble products, an amide and a15
keto-ester.
Scheme 1 (i) Dimethoxypropane, TsOH.H2O, CH2Cl2, 40 °C, 2
h, 80 %; (ii) l-Thr.OMe.HCl, EDCI, cat. HOBt, EtOH, 0 °C to rt,
18 h, 84 %; (iii) SO3.pyr, DMSO, iPr2EtN, CH2Cl2, 0 °C, 3 h; (iv)
PPh3, I2, NEt3, CH2Cl2, 0 °C to rt, 18 h, 32 % over 2 steps; (v)20
AcCl, MeOH, rt, 18h, quant
The AB unit was formed from the tripeptide 14, which was
made by coupling Boc-valine 7 to the deblocked oxazole-amine 8
(scheme 2). The serine residue was then cyclodehydrated using
DAST to give the crude oxazoline, as described by Williams et25
al. in their synthesis of (-)-hennoxazole A.6a. Attempts to oxidise
this using standard conditions (e.g. BrCCl3 and DBU,5f or
BrCCl3, CCl4 and pyridine14) were unsuccessful, presumably due
to the unactivated nature of the oxazoline. Though oxidations of
this type of relatively unactivated oxazoline are not common in30
the literature, examples do exist which use either MnO2 or
NiO2,5i, 11c, 11d which are assumed to follow a similar
mechanism.15 Despite being a widely used oxidising agent, many
procedures do not state the provenance or preparation method of
MnO2, and the method of preparation has been shown to have a35
significant effect on the oxidative ability of the reagent.16
Yokokawa and Shioiri have reported that chemical manganese
dioxide (CMD), manufactured for the production of dry batteries,
is a superior oxidising agent than MnO2 prepared by other
methods.17 We therefore investigated a method of producing40
activated MnO2 proposed by Ball, Goodwin and Morton, where
an aqueous solution of potassium permanganate is reacted with
manganese sulfate in neutral medium to give a precipitate of
MnO2.18 The MnO2 is then activated as required by azeotropic
drying with toluene, as described by Goldman.19 This provides a45
source of MnO2 presumably similar in composition to the CMD,
and indeed a similar technique using benzene-dried CMD was
successfully exploited by Shioiri and Yokokawa for the synthesis
of a variety of thiazole-containing natural products. 20
The oxazoline was treated with an excess of the freshly50
activated MnO2 and, on completion, the residual MnO2 was
reduced using aqueous SO2. A simple aqueous work-up and silica
chromatography gave the clean bisoxazole 4 in 27 % yield over
two steps. It is likely that loss of the N-terminal Boc group during
the reduction of the MnO2 cause the low yield for this step, and a55
more resilient protecting group would undoubtedly have
improved the yield. As this step provided us with sufficient
material to complete the synthesis however, we did not attempt to
optimise it further. One major concern was retaining the
stereointegrity of the N-terminal valine during oxazole synthesis.60
Previous work within the group had identified isoleucine as a
useful residue to detect epimerization by 1H NMR in similar
reactions. Boc-Ile-Ser-OMe was used as a model compound for
oxazole, and we were encouraged to see no apparent
epimerization of the N-terminal stereocentre (see ESI).65
Scheme 2 (i) 7, EDCI, cat. HOBt, NMM, EtOH, rt, 18 h, 88 %;
(ii) DAST, CH2Cl2, -78 °C to rt 2 h; then MnO2, toluene, 110 °C,
6 h, 27 %.
Methyl ester 4 was hydrolysed, and the resulting acid70
underwent an EDCI/HOBt coupling with amine 8 to give the
pentapeptide, 15. Protection of the pendant alcohol to give 16 was
required to prevent beta-elimination during the formation of the
thioamide, which was achieved in excellent yields with
Lawesson’s reagent to give 17. Deprotection of the alcohol75
provided 18, which underwent for a further DAST mediated
cyclodehydration to give the crude thiazoline. This was oxidised
using CCl4 and pyridine to give thiazole 19 in a 27 % yield over 5
steps (scheme 3).
80
Scheme 3 (i) LiOH, H2O, THF, rt, 4h, 99%; then 8, EDCI, cat.
HOBt, NMM, EtOH, rt, 18 h, 73 %; (ii) TBDMSCl, imidazole,
DMF, 0 °C, 3 h, 83 %; (ii) Lawesson's reagent, toluene, THF, 110
°C, 44 h, 81 %; (iii) TBAF, THF, 0 °C, 1 h, 99 %; (iv) DAST,
CH2Cl2, -78 °C to rt 1.5 h; then DBU, pyr., CCl4, MeCN, 0 °C to85
rt, 18 h, 58 % over 2 steps.
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With the synthesis of the four azoles achieved, the completion
of the natural products could be attempted. Saponification of the
methyl ester 19 was more difficult than expected due to its low
solubility, but long reaction times, high dilution and a mixture of
solvents provided the hydrolysis product 20, which was readily5
coupled to isoleucine methyl ester to give the hexapeptide 21.
Removal of the Boc-protecting group allowed coupling 2-
hydroxy-3-methylbutyric acid 22, made from L-valine according
to the method of Bauer and Gajewiak,21 to give alcohol 23. This
alcohol was oxidised to the ketone 24 which was reacted with10
hydroxylamine to give azolemycin A, 1a (scheme 4; 21 steps, 16
steps longest linear sequence, with an overall yield of 0.3 %).
Reaction of ketone 24 with methoxyamine gave azolemycin D,
2b, with a similar yield.
15
Scheme 4, MeOH, THF, CH2Cl2, H2O, rt, 26 h, 92 %; (ii) L-Ile-
OMe.HCl, EDCI, cat. HOBt, NMM, EtOH, rt, 18 h, 84 %; (iii)
NaNO2, H2SO4, H2O, 0 °C to rt, 18 h, 31 %; (iv)a) MeOH,
AcCl,rt, 2 h; b) 22, EDCI, cat. HOBt, NMM, EtOH, 0 °C to rt, 18
h, 90 % over 2 steps; (v) SO3.pyr., NEt3.DMSO, CH2Cl2, 0 °C, 320
h, 65 %; (vi) NH2OH.HCl, pyridine, MeOH, CH2Cl2, rt, 24 h, 58
%; (vii) NH2OMe.HCl, pyridine, MeOH, CH2Cl2, rt, 4h, 62 %.
The 1H NMR spectra of the two synthesized natural products
correlate well with the spectra of the naturally derived molecules.
However, while the naturally derived azolemycins were isolated25
separately as both the E- and Z- oxime isomers, a separation was
not possible for the synthesized product, 1. The synthetic product
consisted mainly of the E-oxime 1a (azolemycin A), with only
traces of the Z-isomer 1b (azolemycin B), based on the valine α-
CH peaks in 1H NMR spectra. In contrast, the synthetic N-30
methoxy azolemycins, 2, were obtained as primarily the Z-
geometric oxime isomer (azolemycin D), but in CDCl3 showed
near complete conversion to the E-isomer (azolemycin C) in
around 5 days.
To extend this project, the synthesis of an azolemycin-like35
tetra-oxazole natural product analogue 30 was attempted. It was
envisaged that any activity shown by the natural product
azolemycin A could be compared with this tetraoxazole
equivalent to observe the requirement, if any, for the C-ring
thiazole. The synthesis of 30 was achieved in a straightforward40
fashion by cyclisation and oxidation of serine-derived precursor
15, forming the C-ring oxazole (scheme 5). This internal oxazole
was formed with comparative ease compared to the N-terminal
oxazole A in the bisoxazole fragment 4. This supports our
hypothesis that, while an adjacent electron withdrawing group at45
the 4-position is important for the oxidation of oxazolines, the
reaction will still proceed in excellent yields if the forming
benefits from conjugation at the 2- and 4-positions with
neighbouring azoles.
50
Scheme 5 (i) DAST, CH2Cl2 then DBU, pyr., CCl4, MeCN, 0 °C
to rt, 72 h, 89 %; (ii) LiOH, H2O, THF, CH2Cl2, 67%; (iii) L-Ile-
OMe.HCl, EDCI, cat. HOBt, NMM, EtOH, 0 °C to rt, 18 h, 54
%; (iv) MeOH, AcCl, rt, 2 h; then 22, EDCI, cat. HOBt, NMM,
EtOH, 0 °C to rt, 18 h, 62 %; (v) SO3.pyr., NEt3.DMSO, CH2Cl2,55
0 °C, 6 h, 72 %; (vi) NH2OH.HCl, pyridine, MeOH, CHCl3, rt,
18h, 33 %.
NMR spectrometry suggests that oxime 30 was formed as a
mixture with the Z-isomer as the major isomer, with the major
peak in the 1H spectrum for the CH adjacent to the oxime at 3.0060
ppm, and the minor peak at 3.49 ppm (compare with 3.50 ppm
for E-1a, 3.00 ppm for Z-1b). Comparison of the 13C NMR
spectra of the tetraoxazole 30 with the equivalent synthesized
azolemycin A 1 showed some distinctive differences. As well as
the obvious shift of the peak corresponding to C32 from 120.265
ppm in 1 to 138.31 ppm in 30, the peaks corresponding to the
other carbons of azole C, and those immediately surrounding it,
were shifted significantly. In particular, in the thiazole 1 the peak
corresponding to B ring carbon C11, occurs at 130.9 ppm, but in
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the oxazole 30 the C11 peak appears at 125.7 ppm. This large
difference in chemical shift may facilitate the identification of the
relative positions of oxazoles and thiazoles in new polyazole
natural products.
5
Figure 5 Numbering for azolemycin A, 1 and tetraoxazole 30.
These syntheses produced azolemycin A and C and the
tetraoxazole analogue 30, for initial biological testing.1 We are
continuing assays in this area.
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